Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands.
Catheter Cardiovasc Interv. 2024 Nov;104(5):1107-1118. doi: 10.1002/ccd.31218. Epub 2024 Sep 11.
Bleeding and stroke are frequent complications after transcatheter aortic valve implantation (TAVI). The mortality risk associated with these events has been reported before, but data regarding their impact on health-related quality of life (QoL) is limited.
To evaluate the impact of bleeding and stroke occurring within 30 days after TAVI, on mortality and QoL during the first year after TAVI.
POPular TAVI was a randomized clinical trial that evaluated the addition of clopidogrel to aspirin or oral anticoagulation in patients undergoing TAVI. Besides clinical outcomes, QoL was assessed using the Short Form-12 and EuroQoL Five Dimensions questionnaires before, and at 3, 6, and 12 months after TAVI.
Major or life-threatening bleeding occurred in 81 patients (8.3%) and was associated with an increased risk of death (hazard ratio [HR] 1.95 [95% confidence interval (CI) 1.00-3.79]); minor bleeding occurred in 104 patients (10.6%) and was not associated with mortality (HR 0.75 [95% CI 0.30-1.89]). Stroke occurred in 35 patients (3.6%) and was associated with an increased risk of death (HR 2.90 [95% CI 1.23-6.83]). Mean mental component summary (MCS-12) scores over time were lower in patients with major or life-threatening bleeding (p = 0.01), and similar in patients with minor bleeding, compared to patients without bleeding; mean physical component summary (PCS-12) scores, EQ-5D index, and visual analog scale (VAS) were similar between those patients. Mean MCS-12 scores were lower in patients with stroke (p = 0.01), mean PCS-12, EQ-5D index, and VAS were similar compared to patients without stroke.
Major or life-threatening bleeding and stroke were associated with an increased risk of death and decreased mental QoL in the first year after TAVI.
经导管主动脉瓣置换术(TAVI)后常发生出血和中风等并发症。这些事件相关的死亡率风险此前已有报道,但有关其对健康相关生活质量(QoL)影响的数据有限。
评估 TAVI 后 30 天内发生的出血和中风对 TAVI 后 1 年内死亡率和 QoL 的影响。
POPular TAVI 是一项随机临床试验,评估了在接受 TAVI 的患者中加用氯吡格雷对比阿司匹林或口服抗凝剂。除临床结局外,还在 TAVI 前以及 TAVI 后 3、6 和 12 个月时使用 12 项简短健康调查问卷(Short Form-12)和欧洲五维健康量表(EuroQoL Five Dimensions)问卷评估 QoL。
81 例患者(8.3%)发生主要或危及生命的出血,且与死亡风险增加相关(风险比 [HR] 1.95 [95%置信区间 1.00-3.79]);104 例患者(10.6%)发生轻微出血,与死亡率无关(HR 0.75 [95% CI 0.30-1.89])。35 例患者(3.6%)发生中风,且与死亡风险增加相关(HR 2.90 [95% CI 1.23-6.83])。与无出血患者相比,主要或危及生命的出血患者的 12 项简短健康调查问卷(Short Form-12)的精神健康成分综合评分(MCS-12)的平均值随时间降低(p = 0.01),而轻微出血患者的 MCS-12 评分与无出血患者相似;与无出血患者相比,轻微出血患者的身体健康成分综合评分(PCS-12)的平均值、EQ-5D 指数和视觉模拟量表(VAS)评分相似。与无中风患者相比,中风患者的 MCS-12 评分平均值较低(p = 0.01),PCS-12、EQ-5D 指数和 VAS 评分相似。
主要或危及生命的出血和中风与 TAVI 后 1 年内的死亡风险增加和精神 QoL 降低相关。